Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Maxamine Therapy enters phase II trial for late-stage RCC

Dec. 4, 1998

Coulter and SB enter agreement to develop and commercialize I-131 anti-B1 antibody

Dec. 4, 1998

Enrollment completed in phase I Biomira lung cancer vaccine trial

Dec. 4, 1998

MDX-210 demonstrates antitumor activity in phase II studies

Dec. 4, 1998

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Dec. 2, 1998

Neurocrine Biosciences advances development of NBI-3001

Nov. 30, 1998

Cell Genesys broadens GVAX trials program in prostate cancer

Nov. 30, 1998

B43-PAP: a promising treatment for Ph+ ALL in development at Hughes Institute

Nov. 30, 1998

PEG-Intron A advances to phase III trials for chronic myelogenous leukemia

Nov. 25, 1998

Novopharm Biotech completes patient enrollment for phase I study of NOVOMAb-G2

Nov. 23, 1998

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...